- Here are the five top insider stock buys from last week.
- Companies include: Krispy Kreme, SentinelOne, Aerovate Therapeutics, Intapp, and Acumen Pharmaceuticals.
Insider is watching which corporate executives are making big bets on their own companies. Here are the five companies that saw the biggest combined stock purchases from insiders during the period from July 2 through July 9, according to data compiled by Insider Monitor.
1. Krispy Kreme – $98,965,594
On July 6 at $16.02 a piece, Austria-based firm Lucresca Se bought 5,882,353 shares of Krispy Kreme, amounting to $94,252,942. Lucresca Se, is an affiliate of JAB Holding, the German conglomerate that took Krispy Kreme private in 2016.
Company chair Olivier Goudet also purchased 294,118 shares on the same day, amounting to $4,712,652.
The donut chain on July 1 returned to the public markets five years. It priced its IPO at $17 per share the previous night, well below its expected range of $21 to $24.
Krispy Kreme in 2016 was acquired by JAB for $21 per share in cash, or a total equity value of about $1.35 billion.
2. SentinelOne – $85,308,944
On July 2, private equity and venture capital firm Insight Partners purchased 202,556 shares of SentinelOne, an American cybersecurity startup, for $35 a piece, amounting to $7,089,460.
New York-based investment adviser Third Point on the same day also purchased 1,765,691 shares at $37.91 a piece, amounting to $66,935,580. It bought 227,884 shares at $49.52 a piece again on July 7, totaling $11,283,904.
SentinelOne on June 30 made its debut on the New York Stock Exchange under the ticker symbol “S.” At market close, its over $10 billion market capitalization made the Mountain View, California-based firm the biggest cybersecurity IPO in history.
3. Aerovate Therapeutics – $70,999,964
On July 2 at $14 a piece, company director Rajeev Shah, who, according to filings, is a constant investor in healthcare companies, purchased 2,785,714 shares, amounting to $38,999,996.
Venture capital firm Atlas Venture and its partner David Grayzel each bought 535,714 shares, amounting to $7,499,996 per transaction as well.
Private equity fund Cormorant Private Healthcare Fund purchased 500,000 shares, amounting to $7,000,000.
James Healy and Katabi Maha, both general partners at Sofinnova Ventures, a biopharmaceutical venture capital firm, each bought 357,142 shares, amounting to $4,999,988 per transaction.
Aerovate Therapeutics, a clinical stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary disease, announced the closing of its initial public offering on July 2.
The company’s initial focus is on advancing a dry powder inhaled formulation for the treatment of pulmonary arterial hypertension.
4. Intapp – $59,800,000
On July 2 at $26 a piece, 10% owner Tembusu Capital purchased 1,920,000 shares of the software startup, totaling $49,920,000, while private equity firm Great Hill Investors bought 380,000 shares, totaling $9,880,000.
The Palo Alto-based business management software company announced the closing of its initial public offering on July 2.
5. Acumen Pharmaceuticals – $59,356,000
On July 6 at $16 a piece, investor Rajeev Shah, who also purchased Aerovate Therapeutics in the same week, purchased 1,875,000 shares, amounting to $30,000,000.
A couple of 10% owners also went on a buying spree. Robert Hardie bought 1,062,500 shares, totalling $17,000,000 while Paul Manning purchased 312,500 shares, amounting to $5,000,000 shares.
Directors John Stalfort John Frank and Nathan Fountain bought 35,000 shares, amounting to $560,000, and 6,250 shares, totaling $100,000 respectively.
Frank Sands, also a 10% owner, bought 450,000 shares but at $14.88 a piece, amounting to $6,696,000.
Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on developing drugs for Alzheimer’s disease, made its debut on the New York Stock Exchange on July 1 under the ticker symbol “ABOS.” The offering closed on July 6.
Business News Governmental News Finance News
Need Your Help Today. Your $1 can change life.